Clinical Trial

Propofol vs Sevo for Paediatric Tumor Surgery

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Background: Retrospective studies and meta-analyses have shown a reduction in 5-year survival following inhalational based compared to propofol based total intravenous (TIVA) anaesthesia for cancer surgery. To date there have been no prospective trials published which evaluate the effect of anaesthetic technique on circulating tumour cells (CTC), oxidative stress, and recurrence rate following cancer surgery. Children with cancer often require surgery for tumour excision as well as for other diagnostic and therapeutic procedures. To date there has been no prospective randomized controlled trial evaluating the optimal anaesthetic technique for surgery on children with cancer. Aim: This is a pilot study in paediatric patients who require surgery for tumour excision. The aim is to investigate the effect of sevoflurane inhalational versus propofol intravenous anaesthesia on expression of hypoxia-inducible factor 1 (HIF-1), circulating tumour cells, DNA damage and biomarkers of immunity and inflammation in patients before and after tumour surgery. The patients will be followed up for up to 5 years for tumour recurrence after surgery. Method: This will be a single-blinded randomized controlled trial. One hundred children undergoing tumour excision surgery at the Hong Kong Children's Hospital will be recruited and randomized to receive TIVA or inhalational anaesthesia. Baseline, intraoperative and postoperative blood will be taken for tests of immunity and inflammatory markers, DNA damage and circulating tumour cells. Patients would be followed up to 3 years for tumour recurrence and survival.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-07-14; most recent amendment 2022-03-14.
Status change: Not Yet Recruiting → Recruiting 2022-03-14
Trial Details
NCT Number NCT04475705
Lead Sponsor Hong Kong Children's Hospital
Collaborators: The University of Hong Kong
Conditions Solid Tumor, Carcinoma, Malignancy, Cancer
Enrollment 100 participants
Start Date 2021-01-11
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2022-03-16